Bronchodilator Drugs - Lesotho | Statista Market Forecast

The projected revenue for Bronchodilator Drugs market in Lesotho is expected to reach US$593.20k in 2024.
This market is anticipated to demonstrate an annual growth rate (CAGR 2024-2029) of 3.93%, leading to a market volume of US$719.40k by 2029.
When compared globally, United States is expected to generate the highest revenue in this market, with an estimated amount of US$17.34bn in 2024.
Lesotho's bronchodilator drug market is experiencing a surge in demand due to the high prevalence of respiratory diseases in the country's mountainous regions.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator Drugs are a type of medication that helps to open up the airways in the lungs, making it easier for people with respiratory problems to breathe. Lesotho, a small country in Southern Africa, has seen a steady increase in the demand for Bronchodilator Drugs over the past few years.

Customer preferences: The demand for Bronchodilator Drugs in Lesotho is largely driven by the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) among the population. The majority of customers who require these medications are adults and the elderly.

Trends in the market: There has been a trend towards the use of combination Bronchodilator Drugs in Lesotho, which are a combination of two or more bronchodilators in a single inhaler. This trend is in line with the global market trend, as combination drugs are considered to be more effective in treating respiratory diseases than single-component drugs. Additionally, there has been an increase in the availability of generic Bronchodilator Drugs in Lesotho, which has helped to make these medications more affordable for customers.

Local special circumstances: Lesotho is a landlocked country with limited resources and a relatively small population. The healthcare system in the country is underdeveloped, and there is a shortage of healthcare professionals and facilities. This has resulted in limited access to healthcare services, including medications such as Bronchodilator Drugs. As a result, many people in Lesotho rely on traditional medicines and home remedies to treat respiratory illnesses.

Underlying macroeconomic factors: The economy of Lesotho is heavily dependent on its textile and garment industry, which accounts for a significant portion of the country's exports. However, the industry has been facing challenges due to competition from other countries and a decline in demand for textiles globally. This has led to a decline in the purchasing power of the population, making it difficult for people to afford expensive medications. Additionally, Lesotho has a high prevalence of HIV/AIDS, which has put a strain on the healthcare system and limited the resources available for the treatment of other diseases.In conclusion, the Bronchodilator Drugs market in Lesotho is driven by the increasing prevalence of respiratory diseases among the population. The trend towards the use of combination drugs and the availability of generic medications has helped to make these drugs more accessible to customers. However, the underdeveloped healthcare system and limited resources in the country pose challenges to the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.